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Aims
To study cGMP metabolism in Nonalcoholic Fatty Liver
Disease (NAFLD) in patients with Morbid Obesity (MO).
Methods
Patients: MO group: 48 patients (40 women and 8 men)
diagnosed of MO with an age of 46.9± 7.9. Control
group: 19 subjects without overweight and with normal
analytical data and normal ultrasound scan of the liver.
The following parameters were measured:
A.- Clinical data: Age, sex, weight, height, abdominal
and hip perimeters, Body Mass Index (BMI), clinical his-
tory and pharmacological treatment, Metabolic Syndrome,
morfometry and haematic chemistry, Insulin Resistance
(HOMA) and viral markers.
B - Immunomodulators: (Leptin, Adiponectin,
CK18Asp396 (CK18), Interleukin-6 (IL-6), aldosterone
and rennin).
C - Histological analysis was performed after obtaining
hepatic tissue during surgery for MO. The NAFLD
Score was calculated: Steatosis Degree, Fibrosis, Inflam-
mation, hepatocyte lesions and other injuries).
Results
The livers of patients can be divided in 4 groups according
to the histological analysis: Normal Liver (2.1 %), Steatosis
(60.4 %), Steatohepatitis (35.4 %), Cirrhosis (2.1 %). We
find higher values of cGMP in plasma from patients with
NAFLD than in the control group (F =2.35; p <0.0001)
and in patients with Steatohepatitis (NASH) than in the
Steatosis group (F=4.02; p=0.025). Analyzing according to
the NAFLD Score, only the fibrosis (F=3.4; p=0.02) shows
differences, with no variations according to grade of Stea-
tosis (p=0.05), neither lobular inflammation (p=0.1) nor
hepatocellular ballooning (p=0.6).
According to the clinical and analytical data studied,
the cGMP level in plasma was higher according to the
waist to hip ratio (p<0.05), Metabolic Syndrome (p<0.05):
There are no significant differences according to HOMA
a n dB M I .W eh a v en o tf o u n ds ignificant correlations
between cGMP and leptin, adiponectin, IL-6, CK-18 or
renin, whereas there was a correlation (Pearson=0.43;
p=0.14) with aldosterone.
Conclusion
There is an alteration in cGMP metabolism in NAFLD
in patients with morbid obesity. This alteration is asso-
ciated mainly with development of hepatic fibrosis with-
out alterations related with Steatosis, inflammation or
hepatocyte lesions. The alteration in cGMP is indepen-
dent of the immunomodulators (leptin, adiponectin,
CK-18, IL-6, aldosterone and renin) studied.
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